Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 9/20 | 0.66 |
| ▸ | FLT3 | P36888 | 9/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.66 |
| ▸ | KIT | P10721 | 3/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1698737 | 0.86 | CSF1R (0.65) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL1698832 | 0.80 | CSF1R (0.70) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL1698701 | 0.80 | FLT3 (1.00) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL1698789 | 0.80 | CSF1R (0.60) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL1698764 | 0.79 | FLT3 (0.75) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL12068461 | 0.78 | CSF1R (0.56) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL9980484 | 0.78 | CSF1R (0.56) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL1698633 | 0.77 | CSF1R (0.53) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL1698956 | 0.77 | CSF1R (0.68) | CSF1RFLT3PDGFRBKITPDGFRA | |
| SCHEMBL20484791 | 0.77 | FLT3 (0.94) | CSF1RFLT3PDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150201-A2 | AZOLYL AMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | CSF1R, CSF3R, ARG1 | CSF1R 1/4885FLT3 4/4885PDGFRB 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.